Beauty Health (SKIN) Teardown: Razor Broke

$300.8 million in revenue. A 65.3% gross margin. Positive operating cash flow for the first time in years. On paper, The Beauty Health Company looks like a turnaround executing on schedule.

Look at the product mix and the balance sheet and the story changes. Device revenue - the razor in the razor/razorblade model - fell from $206.6M to $88.1M in two years, a 57% collapse. The installed base of HydraFacial systems stopped growing. The $750M of 1.25% convertible notes issued at the SPAC peak had to be restructured into $250M of 7.95% secured debt in May 2025, pledging substantially all company assets as collateral. The remaining $124.5M in 2026 Notes matures October 1, 2026 - a current liability sitting against $232.7M in cash.

Three forces are competing simultaneously: the consumable annuity is holding (up +1.8% in FY2025), the gross margin has recovered toward its pre-Syndeo ceiling, and the company has a convertible-notes maturity wall that turns a recovering operating story into a refinancing question. This teardown reads all three.

Section 1 - The snapshot

Metric	FY2025	Q1 FY2026 (most recent)	Q1 FY2025 (prior year)
Revenue	$300.8M	$64.9M	$69.6M
Revenue YoY	-10.0%	-6.7%	n/a
Gross margin	65.3%	68.5%	~69.8%
Operating loss	-$20.8M (-6.9%)	-$1.8M (-2.8%)	-$12.0M (-17.3%)
Net loss	-$9.5M	-$6.6M	-$10.1M
Diluted EPS	-$0.16	-$0.05	-$0.08
Operating cash flow	+$37.5M	-$5.6M	n/a
Cash and restricted cash	$232.7M	$204.4M	n/a
Total debt (face)	$374.5M	~$344.2M (net carrying)	n/a
Adjusted EBITDA (non-GAAP)	$45.1M	$8.5M (+17% YoY)	~$7.3M

The multi-year arc:

Fiscal year	Revenue	YoY growth	Gross margin	Operating margin	OCF
FY2021	$260.1M	+118.4%	68.6%	-15.4%	-$28.4M
FY2022	$365.9M	+40.7%	68.0%	-7.1%	-$106.6M
FY2023	$398.0M	+8.8%	39.0%	-32.9%	+$21.8M
FY2024	$334.3M	-16.0%	54.5%	-20.3%	+$16.1M
FY2025	$300.8M	-10.0%	65.3%	-6.9%	+$37.5M

Product line	FY2023 revenue	FY2023 %	FY2024 revenue	FY2024 %	FY2025 revenue	FY2025 %
Delivery Systems (devices)	$206.6M	51.9%	$125.4M	37.5%	$88.1M	29.3%
Consumables (tips, serums, boosters)	$191.4M	48.1%	$208.9M	62.5%	$212.7M	70.7%
Total	$398.0M	100%	$334.3M	100%	$300.8M	100%

Section 2 - The business model: how they actually make money

HydraFacial is the brand; the business model is capital equipment plus consumables. A medspa or dermatology practice buys a HydraFacial Delivery System (the Syndeo, Elite Tower, or Allegro device) at a premium capital equipment price. Every treatment that device performs requires a minimum of three single-use tips plus proprietary solutions and optional Booster serums - all sold exclusively by the company. The 10-K is direct about the structure: "Delivery Systems follow a traditional capital equipment cycle... Consumables follow a recurring revenue model as Consumables are purchased on a periodic basis by providers as they exhaust their supplies."

That is the razor/razorblade model. The device is the razor; tips and serums are the blades. The financial logic is straightforward: sell a device once and earn an annuity forever. In FY2021 and FY2022, the model was working - gross margin was 68-69%, revenue was doubling and compounding, and Delivery Systems were the growth engine. The SPAC raised $750M on that thesis.

The channel is primarily professional medical, not retail. The 10-K states that approximately 69% of Delivery System and Consumables revenue in the United States and Canada flows through the professional medical channel (dermatologists, plastic surgeons, medical spas). The remaining ~31% goes through esthetician and beauty retail channels (spas, hotels). The company does not disclose a precise DTC/wholesale/retail/marketplace percentage split - the 10-K does not report those breakdowns. Geographically, approximately 35% of FY2025 net sales came from markets outside the United States and Canada.

Where does the 65.3% gross margin come from? Two things. First, the professional-channel model bypasses the multi-step retail markup that compresses gross margin for consumer beauty brands. When a medspa buys Consumables for $X, there is no retailer taking a 40% cut between the manufacturer and the end user. Second, mix shift: as Delivery Systems (lower margin per dollar at scale) collapsed and Consumables (higher recurring-purchase margin) became 70.7% of revenue, the blended gross margin mechanically rose. Cost of sales fell from $242.9M (FY2023) to $104.4M (FY2025) even as gross profit rose from $155.1M to $196.4M.

The TikTok embeds below show the treatment from the provider and consumer side - and the skeptic side. All three are category and sentiment signals, not financial evidence.

@averyywoods

My skin was THIRSTY most relaxing two hours #fyp #hydrafacial #skincare #facial #selfcare

♬ original sound - Avery Woods

@averyywoods, 513.5K plays, 39.2K likes. Consumer demand signal: a treatment ASMR vlog with strong engagement shows the HydraFacial experience travels well on social. The 39K likes on an organic post signals genuine consumer affinity, not just brand-push content. Social signal only.

@elevenesthetician

LETS TALK HYDRAFACIAL with your estheticians favorite esthetician :) #skincare #hydrafaical #esthetician #glassskin

♬ original sound - elevenesthetician

@elevenesthetician, 145.7K plays, 4.1K likes. Provider-side signal: an esthetician explaining HydraFacial to her audience shows the treatment has professional credibility and that providers are using social content to drive treatment bookings. Social signal only.

@jc.dombrowski

Yeah this is another #skincare scam i see everywhere! #skincaretips #science #hydrafacial #beauty

♬ original sound - J.C. Dombrowski

@jc.dombrowski, 133.2K plays, 3.6K likes. Consumer skepticism signal: a #skincarescam framing of HydraFacial with 133K plays and 227 comments. This is the counter-narrative that lives alongside the demand signal. Consumer skepticism about efficacy is a real demand risk for the installed base utilization rate. Social signal only.

Section 3 - Strengths: the moat that is real

1. HydraFacial is the category-defining brand in hydradermabrasion - with a 36,000+ device installed base. The 10-K describes HydraFacial as "the pioneer" of the hydradermabrasion category. Management cited an active installed base of 36,419 Hydrafacial Delivery Systems as of Q1 2026 (per the May 7, 2026 earnings press release). That is not a marketing number - it is the physical footprint that generates every Consumables dollar. Each of those devices is in a medspa or clinic performing treatments that require SKIN's single-use tips and serums. No competitor has an equivalent installed base in this specific procedure category. The brand is genuinely embedded in the professional aesthetic channel in a way that is difficult to displace without a major device refresh cycle. Source: SKIN 10-K FY2025 Item 1; SKIN Q1 FY2026 earnings press release, GlobeNewswire, May 7, 2026.

2. A 65.3% gross margin approaching its pre-Syndeo ceiling, with Q1 FY2026 at 68.5%. The gross margin recovery is real and sourced. FY2023 collapsed to 39.0% because $65.2M of Syndeo charges went through cost of sales - that was a one-time event, not a structural margin problem. With those charges cleared and the Consumables mix rising to 70.7% of revenue, gross margin has climbed back toward the 68-69% level that characterized the pre-Syndeo business. Adjusted gross margin was 68.2% for full-year FY2025. Q1 FY2026 GAAP gross margin was 68.5% - the strongest in company history. The professional-channel model - bypassing retail markup entirely - is what enables margin at this level. Source: SKIN 10-K FY2025; SKIN Q1 FY2026 press release, StockTitan, May 7, 2026.

3. OCF turned and is positive: $37.5M in FY2025, the best since the SPAC. Operating cash flow was -$106.6M in FY2022, turned mildly positive in FY2023 (+$21.8M on a working-capital benefit), dipped to +$16.1M in FY2024, and expanded to +$37.5M in FY2025. This is not GAAP income (the company posted a net loss of -$9.5M). It is real cash generated from operating the business before debt service and investing activities. On an Adjusted EBITDA basis, the company generated $45.1M in FY2025. That $37.5M in OCF, sustained and growing, is the primary argument that the operating business has stabilized - not the GAAP net loss line, which is distorted by interest expense on the 2028 Notes ($19.9M/year) and non-cash items. Source: SKIN 10-K FY2025 cash flow statement.

4. Cost discipline is real: OpEx fell 13.2% in FY2025 even as gross profit rose. Total operating expenses fell from $250.1M (FY2024) to $217.2M (FY2025) - a $32.9M reduction. Selling and marketing dropped from $118.3M to $93.6M; G&A from $125.5M to $117.9M. The operating loss shrank from -$67.8M to -$20.8M not through revenue growth but through cost discipline. In Q1 FY2026, G&A fell -34.6% YoY to $21.9M, driving a swing from a -17.3% operating margin to -2.8% on only -6.7% revenue. This is the evidence of a management team that is running hard on cost structure while revenue stabilizes. Source: SKIN 10-K FY2025 income statement; SKIN 10-Q Q1 FY2026.

Section 4 - Weaknesses: the cracks in the 10-Q

1. Delivery Systems fell 57% from peak - the installed base is not growing, it is aging. The 10-K states this risk explicitly and verbatim: "Our business is dependent on the commercial success and our ability to sell Delivery Systems. If we are unable to continue to successfully commercialize and sell our Delivery Systems, our results of operations and financial condition will be materially harmed." Delivery Systems revenue went from $206.6M (FY2023) to $125.4M (FY2024) to $88.1M (FY2025) - a 57% decline in two years. In Q1 FY2026, device placements were 746 units vs 862 in Q1 FY2025, a further -13.5% drop. An installed base of ~36,000 devices generates the Consumables annuity, but devices have finite useful lives. Without new placements growing the base, replacement cycles eventually reset demand. The razor/razorblade thesis requires continuous device sales to grow the annuity; SKIN is running the annuity on a fixed (or declining) asset base. Source: SKIN 10-K FY2025, Note 16 and risk factors; SKIN Q1 FY2026 press release.

2. The 2026 Notes ($124.5M face, current liability) mature October 1, 2026 - a refinancing question against $232.7M in cash. The math looks manageable: $232.7M in cash against a $124.5M current maturity suggests the company can pay it off directly. But read the full balance sheet. After retiring the 2026 Notes (~$124.5M), remaining cash is approximately $108M. The 2028 Notes ($250M face, 7.95% coupon) require approximately $19.9M in annual interest payments for the next three years plus the $250M principal at maturity (November 2028). OCF of $37.5M in FY2025 covers the annual interest; it does not address the principal. If revenue continues declining in FY2026 (guidance was cut to $280-$295M midpoint, from an initial $285-$305M per the Q1 2026 earnings transcript), the operating cushion narrows. And the 2028 Notes are secured with a first-priority lien on substantially all assets - a covenant structure that gives secured lenders priority over every other claim in a restructuring scenario. Source: SKIN 10-K FY2025; SKIN Q1 FY2026 earnings transcript, The Motley Fool, May 9, 2026.

3. The 2028 Notes carry a $2.86/share conversion price - potential dilution of ~87.4M shares on a 127.5M share base. This is the dilution sword hanging over any equity recovery. The original 2026 Notes had a conversion price of $31.76/share - the SPAC-era stock price that never returned. The May 2025 restructuring issued the new 2028 Notes at a $2.86/share conversion price (vs. a stock price that has traded well below $5). At full conversion, the 2028 Notes would add approximately 87.4M shares to the current count of 127.5M - a 69% dilution. Even if the company's operating trajectory improves, equity value recovery faces a structural ceiling from this conversion overhang. The 10-K risk factors note this directly: "any conversion of Notes will dilute the ownership interests of existing stockholders." Source: SKIN 10-K FY2025, Note 7 (Convertible Senior Notes) and balance sheet.

4. APAC collapsed and the material weakness signaled governance fragility. APAC fell from $82.2M (FY2023) to $28.5M (FY2025) - a $53.7M revenue hole created by a single regional decision: transitioning China from direct sales to a distributor. The 10-K flags the channel risk verbatim: "We are dependent upon the success of our distributors. If our distributors fail to adequately market and sell our products... our revenues and profitability could be adversely affected." Meanwhile, the FY2024 10-K disclosed a material weakness in internal controls over financial reporting related to inventory physical counts, excess/obsolete estimation, and purchase controls - an adverse ICFR opinion from Deloitte. The weakness was remediated by Q4 2025, and Deloitte issued an unqualified opinion on FY2025 ICFR. But the pattern - two CEO departures, a material weakness, a SPAC-era restatement on warrant accounting - signals governance fragility that erodes investor confidence precisely when the operating business needs credibility most. Source: SKIN 10-K FY2025 Item 9A; SKIN 10-K FY2024 risk factors.

Section 5 - Opportunities and threats

The opportunity side for SKIN is real but requires execution the company has not yet demonstrated.

The most immediate opportunity is installed base reactivation. Management disclosed in the Q1 2026 earnings transcript that device "churn declined 40% year-over-year" - meaning providers are staying with HydraFacial longer. The Q1 2026 press release also referenced "provider retention and reactivation programs." If the 36,419-unit active installed base can be managed more tightly - activating low-utilization accounts, reducing churn, and increasing treatment frequency - Consumables revenue can grow without requiring new device placements. That is the near-term lever that does not depend on fixing device sales.

Next-generation device development is mentioned in the FY2025 10-K as in progress. A successful device refresh - one that avoids the Syndeo 1.0/2.0 fluidics failure - would restart the device sales cycle and, more importantly, grow the installed base again. Without installed base growth, the consumable annuity has a ceiling at whatever the current device count generates. Management has not disclosed a launch timeline for a next-generation device.

The medspa channel is experiencing private equity consolidation and roll-up activity. That is a two-sided dynamic: large multi-site operators become more powerful purchasers and can demand better economics (a threat), but they also commit to platform devices for multiple locations simultaneously (an opportunity for Delivery Systems volumes). If SKIN can sign enterprise agreements with roll-up operators, it could stabilize Delivery Systems revenue without relying on individual spa-by-spa sales cycles.

The threats are concentrated and structural.

The primary credit threat is the maturity sequence. Pay off $124.5M in October 2026. Service $250M in 7.95% secured debt through November 2028. The company has $232.7M in cash and generated $37.5M in OCF in FY2025. The arithmetic works if revenue stabilizes - it becomes fragile if the FY2026 guidance cut is the first of multiple cuts. A second revenue decline year on top of the already-reduced guidance erodes the cash cushion against the 2028 maturity.

The broader threat is aesthetic spend discretionary cyclicality. HydraFacial treatments are elective cosmetic services. When consumer confidence drops or credit tightens, medspa operators buy fewer devices and consumers book fewer treatments. The 10-K acknowledges this explicitly: revenue could be "adversely affected by recessionary economic conditions," and medspa capital purchases are financed against future treatment revenue that itself is subject to consumer discretionary fluctuations.

At-home device alternatives represent a long-term structural threat to the in-clinic treatment category. As consumer-grade hydradermabrasion devices improve (several Chinese manufacturers have introduced lower-cost alternatives), some consumers substitute at-home devices for the professional treatment. This is a slow-moving threat but one that erodes the total addressable treatment occasion count over time.

Section 6 - The macro environment

HydraFacial flies through three macro forces that point in different directions.

Medical aesthetics demand is structurally growing. The global medical spa market was estimated at approximately $24.2B in 2025, with mid-to-high single-digit CAGR projections through 2030 (per industry market reports and sell-side research notes cited in dated financial press). Professional aesthetic treatments - hydradermabrasion, RF microneedling, laser resurfacing - are increasingly viewed by consumers as accessible wellness services rather than luxury indulgences. The consumer wallet shift toward experiences over goods has supported the medspa category. That tailwind benefits SKIN's installed base utilization rates: more treatments per device means more Consumables per year.

Consumer credit conditions are the near-term macro headwind that SKIN cannot outrun. Medspas and aesthetic practices finance device purchases - a Syndeo device costs several thousand dollars upfront - against anticipated future treatment revenue. When the Fed holds rates high or consumer credit tightens, small business borrowers (the medspa owner) defer capital equipment purchases. This is the explicit driver cited in the FY2025 10-K and the Q1 2026 earnings transcript for Delivery Systems weakness: "unfavorable macroeconomic and credit conditions." Device placement counts fell from 862 in Q1 FY2025 to 746 in Q1 FY2026. That is not a brand problem - it is a credit-cycle problem that would affect any capital equipment seller to small medical businesses.

Tariff exposure is a new and explicit cost risk for SKIN. The Q1 FY2026 guidance statement includes: "Guidance presumes no further material deterioration from tariffs, trade restrictions, or foreign currency exchange rates." The FY2025 10-K flags tariff risk on imported components and consumable raw materials. A significant share of the device component supply chain and consumables manufacturing involves Asian suppliers, creating direct cost exposure to any escalation in U.S.-China tariffs. Management has flagged this as a first-order margin risk for FY2026, not a back-of-the-envelope sensitivity.

APAC macro is a structural hole that compounds the distributor transition. China's aesthetic device market faced both macro weakness and regulatory scrutiny of medical aesthetics practices in FY2024-2025. The transition to a distributor in Q2 2025 was partly a response to those conditions. Rebuilding distributor relationships in a market with regulatory uncertainty is a multi-year process with no guaranteed outcome. APAC at 9.5% of FY2025 revenue is a much smaller contributor than the 20.7% it was in FY2023 - but that also means any recovery there would be incremental upside, not a structural fix for the total revenue picture.

Section 7 - The CFO verdict and the operator bridge

Here is the read on SKIN from a CFO's vantage point.

Where the Street's read sits. The consensus on SKIN is cautiously constructive on the operational recovery and uncertain on the capital structure resolution. Sell-side research notes and the financial press (as of June 2026) generally acknowledge that the gross margin recovery is real, OCF is positive, and the operating loss is narrowing fast. The Q4 FY2025 quarter saw the first positive operating income since the post-SPAC expansion period ($0.2M operating profit). The bear camp focuses on three things: (1) three consecutive quarters of top-line contraction with a guidance cut, (2) the $124.5M October 2026 maturity wall requiring cash deployment before operations fully recover, and (3) the 87M share dilution overhang from the 2028 Notes at $2.86/share conversion. The most bearish read holds that even if operations recover, equity holders face a dilution event that limits the upside.

Where I agree and where I differentiate. The bulls are right that the operational recovery is real. A business that earns 65.3% gross margin, generated $37.5M in OCF, and cut its operating loss from -$67.8M to -$20.8M in a single year is demonstrably not in freefall. The cost discipline is genuine - G&A fell -34.6% in Q1 FY2026 alone. The Consumables annuity is holding: +1.8% growth in a year when device sales fell -29.8% proves the installed base generates recurring revenue independent of new placements.

The bears are right that the October 2026 maturity is the near-term test. The math says SKIN has enough cash ($232.7M) to retire the $124.5M 2026 Notes and still have a buffer. But paying off $124.5M leaves approximately $108M to service $250M of 7.95% secured debt for three years - roughly $19.9M in annual interest plus the $250M principal in November 2028. OCF of $37.5M in FY2025 covers the interest. It does not replenish cash for the 2028 principal. The company will need to either refinance the 2028 Notes before maturity, generate substantially more OCF, or raise equity - and any equity raise at current valuations plus the $2.86 conversion overhang is materially dilutive.

Where I differentiate from both: the deepest risk at SKIN is not the 2026 maturity (manageable with existing cash) and not even the 2028 maturity (manageable if OCF compounds). It is the installed base math. If Delivery Systems placements continue declining - 862 in Q1 FY2025, 746 in Q1 FY2026, a -13.5% step-down - the active installed base eventually shrinks as old devices age out. A 36,000-device installed base generating $212.7M in Consumables is the company's entire cash engine. If that installed base declines to, say, 30,000 devices over the next three years due to end-of-life attrition without replacement, Consumables revenue does not grow at 1.8% - it shrinks. The device refresh cycle is the real clock ticking underneath the OCF recovery.

The open levers, in order of feasibility: (1) refinance or extend the 2026 Notes cleanly - already executed in May 2025 for the bulk of the position; the remaining $124.5M should be manageable with existing cash; (2) stabilize the installed base through provider retention programs (churn already declining -40% per Q1 2026 call); (3) lean on cost discipline to continue compressing the operating loss toward breakeven; and (4) execute the next-generation device launch successfully - this is the longest-dated but most important lever, because it is the only way to restart installed base growth and with it the Consumables compounding engine. Prescribing a price cut on device hardware to stimulate volume is structurally infeasible: device revenue at $88M is already compressed, and cutting price would damage gross margin and cash conversion without guaranteeing volume recovery against a credit-constrained customer base.

The operator bridge. Your $5-80M brand almost certainly has a version of the SKIN pattern, and it is worth naming precisely. The razor/razorblade model - where you sell a device or product once to create a recurring consumable annuity - is one of the most attractive business structures in consumer goods. HydraFacial proved it works: $212.7M in Consumables revenue flowing from an installed base of 36,000+ devices even in a year when device sales fell 30%.

But the SKIN pattern reveals the critical break point. The model depends on two conditions simultaneously: the installed base must grow (or at minimum hold), and the consumable annuity per device must compound. When device sales collapse - for any reason, whether a product failure like Syndeo or a credit cycle crunch - the installed base ages in place. Each device has a useful life. Over time, devices reach end-of-life, providers switch to competitors, or providers simply exit the business. If the base is not continuously refreshed with new device sales, the consumable annuity eventually erodes from the top line downward.

I have seen this pattern with subscription SaaS companies that nail the initial sale and ignore churn. Revenue looks stable until the underlying cohort math catches up - and then the decline is fast because it is structural, not cyclical. For a medspa device company, the equivalent is exactly what SKIN is now measuring: the rate at which installed devices are reactivated, replaced, or lost to attrition vs. the rate at which new devices are placed. The 40% churn reduction disclosed in Q1 2026 is the right metric to watch. It tells you whether the installed base is stabilizing before device sales recover.

For your brand: if you have a razor/razorblade model - a device, a subscription, an initial-sale-plus-consumables structure - the signal to watch is not your gross margin or even your total revenue. It is the cohort math: how many "razors" are active and how many consumable units per razor per month? If the razor count is flat or declining, the consumable line will follow. Map it monthly. It is the lead indicator your income statement will not show you for 12-24 months.

Early-warning scorecard - five lines that catch the razor/blade break 12 months early:

1. Installed base unit count vs. prior period: If you have a device-plus-consumables model and you are not tracking active units in the field on a monthly basis, you cannot see the break coming. SKIN does not even disclose its installed base count publicly - a governance gap that limits investor visibility. Track it internally even if you do not publish it. When unit count starts declining, consumables follow within 4-8 quarters.

2. Consumables revenue per installed unit per period: This is the utilization rate. If total Consumables revenue is holding but the installed base is growing, utilization per unit is falling - a warning sign. If both are flat and the base is shrinking, you are running the annuity on a depleting asset. Calculate: Consumables revenue / active device count / quarter. Watch the trend, not the level.

3. New unit placements vs. estimated end-of-life retirements: Device placements (746 in Q1 FY2026) need to exceed the estimated end-of-life retirements from the installed base each period for the base to grow. If you do not know your average device useful life, you cannot calculate this. For a $300M business, this math should be in a CFO dashboard. For a $10M business with a device-led model, it absolutely should too.

4. Gross margin by product line, not blended: SKIN's blended 65.3% gross margin obscures the margin difference between Delivery Systems and Consumables. If your blended margin is rising while your high-margin product line is shrinking, the mix shift is temporarily flattering your P&L. Separate the margin by product type and watch both trends independently.

5. Debt service coverage against OCF: The 2028 Notes require $19.9M in annual interest from a business generating $37.5M in OCF. That is a 53% debt-service-to-OCF ratio before any principal repayment. For your business: take your annual loan or lease payments, divide by OCF, and watch the ratio. If it exceeds 40-50%, a single bad quarter of OCF can put you in a technical covenant breach or a cash-crunch position. At SKIN's size this is existential; at a $10M DTC brand with a $2M SBA loan and $500K in OCF, the math is similarly unforgiving.

If you want to run this scorecard against your own numbers before the break shows up in revenue, that is a fractional CFO conversation. The analysis takes a few hours to set up. The cost of not doing it arrives when the consumables line starts declining and you realize the installed base math has been telling you for 18 months.

Related teardowns and live indexes

For more teardowns of beauty and personal-care brands, see Estee Lauder and Coty, and The Honest Company. To benchmark Beauty Health against the public-DTC field and track the input costs squeezing the category, follow the Public DTC Leaderboard and the DTC Cost-of-Goods Index.

Sources and methodology

SEC EDGAR is the primary source for every financial figure in this post. The Beauty Health Company (CIK 0001818093) files on SEC EDGAR under the 10-K and 10-Q form types. Specific filings used: 10-K FY2025 (filed 2026-03-12, accession 0001628280-26-017376, document skin-20251231.htm); 10-Q Q1 FY2026 (filed 2026-05-07, accession 0001628280-26-032326, document skin-20260331.htm); 10-K FY2024 (filed 2025-03-12, accession 0001628280-25-012407); 10-K FY2023 (filed 2024-03-12, accession 0001628280-24-010638). Revenue, gross margin, operating income/loss, net income/loss, OCF, inventory, debt, and product line/geographic disaggregation are taken directly from the financial statements, notes, and MD&A in these filings.

The Syndeo failure narrative is sourced verbatim from the FY2023 10-K (skin-20231231.htm) MD&A section on the Syndeo Enhancement Program: "A significant issue was low flow and clogs in the system, due to recommended maintenance requiring overly rigorous levels to prevent serum build-up inside the system's fluidics manifold." The $65.2M charge breakdown ($45.6M upgrades/replacements + $19.6M inventory write-down) is from the same filing's cost-of-sales breakdown.

The 2026 Notes restructuring terms (May 2025 exchange of $263.2M face at 95 cents for $250M new 7.95% secured 2028 Notes; separate cash repurchases of $150.1M face for $142.6M) are from the FY2025 10-K MD&A "Liquidity and Capital Resources" section and Note 7 (Convertible Senior Notes). The $2.86/share conversion price and first-priority lien structure are from Note 7.

The installed base count (36,419 active devices as of Q1 2026) is from the SKIN Q1 FY2026 earnings press release published on GlobeNewswire/StockTitan, May 7, 2026. This figure is not disclosed in the 10-K or 10-Q; it is management-disclosed non-GAAP operational data from the earnings press release. The FY2025 and FY2024 10-Ks do not disclose a specific installed base count, referencing only a "large installed base of Hydrafacial systems across provider practices worldwide" qualitatively.

The leadership and CEO timeline is sourced to the GlobeNewswire press release dated September 30, 2025 (Pedro Malha named President and CEO effective October 1, 2025) and the Business of Fashion article dated October 2, 2025 (Malha from Abbott succeeding Marla Beck).

The analyst consensus and Street thesis is synthesized from sell-side research notes and dated financial press (linked below). Individual analyst price targets and ratings are directionally described; they are not quoted from a specific firm's formal published report.

Limitations. The company does not disclose a specific installed base count in its 10-K or 10-Q filings; the 36,419 figure is from the earnings press release and is unaudited management-disclosed data. The company does not disclose a product-line margin split (Delivery Systems vs Consumables gross margin separately) - only the blended gross margin is reported. The adjusted gross margin (68.2% FY2025, 68.5% Q1 FY2026) is a non-GAAP measure excluding stock-based compensation, amortization, and one-time items per management's reconciliation. No going-concern language appears in the FY2025 10-K; Deloitte issued an unqualified audit opinion dated March 12, 2026. The October 2026 2026 Notes maturity had not been refinanced as of the 10-K filing date. This post reflects filings and disclosures current through June 25, 2026.

External sources: - SEC EDGAR FY2025 10-K filing index - CIK 0001818093 - SEC EDGAR Q1 FY2026 10-Q filing index - SKIN Q4 FY2025 earnings release, GlobeNewswire, March 12, 2026 - SKIN Q1 FY2026 earnings transcript, The Motley Fool, May 9, 2026 - Pedro Malha CEO appointment, GlobeNewswire, September 30, 2025

Frequently asked questions

what does the beauty health company sell?

The Beauty Health Company sells HydraFacial, a hydradermabrasion device (Delivery System) used by medspas, dermatologists, and estheticians, plus the recurring single-use Consumables - tips, serums, and Boosters - required for each treatment. In FY2025, Consumables were $212.7M (70.7% of revenue) and Delivery Systems were $88.1M (29.3%). The company also sells HydraScalp and SkinStylus devices, though HydraFacial is the dominant franchise. Source: SKIN 10-K FY2025, Note 16.

why did beauty health's gross margin collapse to 39%?

The Syndeo device - launched March 2022 - had a design flaw: fluidics manifold clogging caused by maintenance protocols that were too rigorous for typical medspa staff. The company acknowledged the root cause verbatim in its 10-K: "low flow and clogs in the system, due to recommended maintenance requiring overly rigorous levels to prevent serum build-up inside the system's fluidics manifold." The fix cost $65.2M in FY2023 COGS charges - $45.6M for field upgrades and replacements, $19.6M for inventory write-downs. That single year took gross margin from 68.0% to 39.0%. Source: SKIN 10-K FY2023.

what are the beauty health 2026 convertible notes?

The Beauty Health Company issued $750M of 1.25% Convertible Senior Notes in September 2021 (SPAC proceeds) due October 1, 2026. As of December 31, 2025, $124.5M face remained outstanding and was reclassified as a current liability. In May 2025, the company exchanged $263.2M face of 2026 Notes for $250M of new 7.95% secured 2028 Notes (first-lien on substantially all assets) and repurchased another $150.1M face for $142.6M cash. The $124.5M balance is due in full by October 1, 2026. Source: SKIN 10-K FY2025.

is beauty health's consumables annuity model working?

Partly. Consumables grew +1.8% in FY2025 to $212.7M, even as Delivery Systems fell -29.8% - evidence the installed base generates recurring revenue independent of new device placements. But growth is anemic, not compounding. The 10-K does not disclose the installed base count. Sell-side research and a May 2026 press release cited an active installed base of 36,419 devices as of Q1 2026. Without new device placements growing the base, the consumable annuity has a ceiling. Source: SKIN 10-K FY2025; SKIN Q1 2026 earnings release.

how much debt does beauty health have?

At December 31, 2025, The Beauty Health Company had $374.5M in total debt face: $124.5M of 1.25% 2026 Convertible Notes (current liability, due October 2026) and $250.0M of 7.95% Senior Secured Notes due November 2028 (first-priority lien on substantially all assets). Against $232.7M in cash and restricted cash, net debt was approximately $141.8M. The 2028 Notes carry a conversion price of approximately $2.86 per share, implying potential dilution of ~87.4M shares on a current share count of 127.5M. Source: SKIN 10-K FY2025.

what happened to beauty health in apac?

APAC revenue fell from $82.2M in FY2023 to $45.7M in FY2024 (-44%) and further to $28.5M in FY2025 (-37.6%), a 65% total decline over two years. The primary driver was China: the company transitioned from a direct sales model to a distributor in Q2 2025, disrupting both device and consumables sales. APAC fell from 20.7% of revenue in FY2023 to 9.5% in FY2025. Rebuilding the China distributor channel takes years and is not guaranteed. Source: SKIN 10-K FY2025, Note 16; SKIN 10-Q Q1 FY2026.

who is the ceo of beauty health?

Pedro Malha became President and CEO of The Beauty Health Company effective October 1, 2025, succeeding interim CEO Marla Beck. Malha previously held executive roles at Abbott Laboratories. CFO Michael Monahan has been in seat since August 10, 2023. The company also renamed itself SkinHealth Systems Inc. in April 2026 as part of its repositioning away from the "Beauty Health" brand identity. Source: GlobeNewswire, September 30, 2025; Business of Fashion, October 2, 2025.

what is beauty health's gross margin recovery and where does it stand?

SKIN's GAAP gross margin hit a trough of 39.0% in FY2023 due to $65.2M in Syndeo-related COGS charges. It recovered to 54.5% in FY2024 (charges cleared) and 65.3% in FY2025 (mix shift to higher-margin Consumables, lower inventory reserves). Q1 FY2026 printed 68.5% - the strongest in company history and approaching the pre-Syndeo peak of ~68-69%. The adjusted gross margin was 68.2% for full-year FY2025. Source: SKIN 10-K FY2025; SKIN Q1 FY2026 press release, May 7, 2026.